Neoleukin Therapeutics, Inc. (NLTX): Price and Financial Metrics
NLTX Price/Volume Stats
| Current price | $13.96 | 52-week high | $14.36 |
| Prev. close | $3.44 | 52-week low | $2.03 |
| Day low | $13.68 | Volume | 28,275 |
| Day high | $14.36 | Avg. volume | 50,104 |
| 50-day MA | $3.47 | Dividend yield | N/A |
| 200-day MA | $3.72 | Market Cap | 131.20M |
NLTX Stock Price Chart Interactive Chart >
Neoleukin Therapeutics, Inc. (NLTX) Company Bio
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops medicines to treat serious diseases, including cancer, inflammatory, and autoimmune disorders.
Latest NLTX News From Around the Web
Below are the latest news stories about NEOLEUKIN THERAPEUTICS INC that investors may wish to consider to help them evaluate NLTX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! |
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. |
BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncFirm real-time pick highlight |
Neurogene and Neoleukin Announce Definitive Merger AgreementProposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene’s differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approximately $95 million from concurrent private financing by Neurogene’s new and existing investors Cash expected to fund combined company into 2H:26 and through multiple catalysts, including preliminary data in 4Q:24 and addit |
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring PlanNeoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce. |
NLTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -0.29% |
| 1-year | -17.82% |
| 3-year | -94.67% |
| 5-year | -73.86% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -89.44% |
| 2021 | -65.82% |
| 2020 | 14.45% |
| 2019 | 470.37% |
Loading social stream, please wait...